Release date: 31 May 2013
Promoter – Financial Intermediary
H. LUNDBECK A/SLocation
Description
Financing Lundbeck’s Neurology R&D for the 2013-2015 period for the development of new innovative patented drugs for the treatment of CNS diseases with high unmet medical need.
Objectives
The project concerns the research and development (R&D) activities oriented towards disorders of the central nervous system including Parkinson’s and Alzheimer ’s disease, whereby a defect of the synaptic transmission within the nerve cells is a cause of the disease. It covers different stages of development including pre-clinical and clinical studies.
Sector(s)
Proposed EIB finance (Approximate amount)
EUR 150 million
Total cost (Approximate amount)
EUR 392 million
Environmental aspects
The project mainly concerns investments in R&D that are expected to be carried out in existing facilities already authorized for the same purpose and would therefore not require an Environmental Impact Assessment (EIA) under the Directive 2011/92/EU. Full environmental details will be verified during the appraisal.
Procurement
The promoter is a private company not operating in the Utilities sector and not having the status of a contracting authority. Thus it is not covered by EU Directives on procurement.
Status
Signed - 23/10/2013
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).